Struthers A D
Department of Clinical Pharmacology, Ninewells Hospital, Dundee, UK.
Eur Heart J. 1997 Nov;18 Suppl E:E5-8. doi: 10.1016/s0195-668x(97)90002-6.
It is 10 years since the CONSENSUS I study showed that ACE inhibitors improved mortality in heart failure. This finding has been confirmed in numerous trials, for example SOLVD, SAVE. Indeed, in the intervening 10 years, many other potential therapies have been examined in mortality trials, but so far no other therapy has had as good effect on mortality as ACE inhibitors. The other therapies which have been examined are digoxin, amlodipine, beta-blockers, amiodarone, etc. Despite ACE inhibitors being a very effective therapy for heart failure, there is still remarkable under-use of them in clinical practice. The reason for this needs to be explained further, but fear of hypothermia and renal dysfunction appear to be major factors.
自“共识 I”研究表明血管紧张素转换酶(ACE)抑制剂可改善心力衰竭患者的死亡率以来,已经过去10年了。这一发现已在众多试验中得到证实,例如“左室功能不全研究(SOLVD)”、“生存与心室扩大研究(SAVE)”。的确,在这期间的10年里,许多其他潜在疗法也在死亡率试验中接受了检验,但到目前为止,没有其他疗法对死亡率的影响能与ACE抑制剂相媲美。接受检验的其他疗法包括地高辛、氨氯地平、β受体阻滞剂、胺碘酮等。尽管ACE抑制剂是治疗心力衰竭的一种非常有效的疗法,但在临床实践中其使用仍明显不足。对此原因需要进一步解释,但对低血压和肾功能不全的担忧似乎是主要因素。